Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma MarPHMMF 69 3-Year EBITDA Growth Rate is 11.70% as of Jun. 2026. GuruFocus rates PHMMF with a GF Score™ of 69/100 and a GF Value™ of $92.19 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,131 Biotechnology companies, Pharma Mar ranks worse than 54.29% on this metric.
During the past 12 months, Pharma Mar's average EBITDA Per Share Growth Rate was -6.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -26.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Pharma Mar was 55.70% per year. The lowest was -69.00% per year. And the median was -1.40% per year.
Pharma Mar (OTCPK:PHMMF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Pharma Mar 3-Year EBITDA Growth Rate Related Terms
PHMMF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Pharma Mar's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Pharma Mar's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.70% mean?
Pharma Mar (PHMMF) has a 3-Year EBITDA Growth Rate of 11.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pharma Mar and its competitors. According to the industry distribution chart, Pharma Mar ranks #614 out of 1131 companies in the Biotechnology industry, placing it in the top 54.3%.
Is Pharma Mar's 3-Year EBITDA Growth Rate too high?
Pharma Mar's current 3-Year EBITDA Growth Rate is 11.70%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Pharma Mar's value of 11.70% is 21.5% below this industry median. Based on the distribution chart, Pharma Mar ranks #614 out of 1131 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharma Mar has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #614 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Pharma Mar in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Pharma Mar's value of 11.70% is 21.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Mar's current 3-Year EBITDA Growth Rate of 11.70% is 21.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Pharma Mar and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Mar's current 3-Year EBITDA Growth Rate is 11.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Fairly Valued. The stock's GF Value™ is $92.19, compared to a current price of $87.58 — trading 5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 11.70% and 21.5% below the Biotechnology industry median of 14.90. Pharma Mar's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current 3-Year EBITDA Growth Rate is 11.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (PHMMF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of $87.58 is trading 5% below its estimated GF Value™ of $92.19.
GuruFocus considers Pharma Mar to be Fairly Valued.
Key valuation signals for PHMMF:
3-Year EBITDA Growth Rate: 11.70%
GF Value™: $92.19 vs. price of $87.58 (5% below fair value)
Industry Position: 21.5% below the Biotechnology median (#614 of 1131)
No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
69GF Score
Get the complete analysis for PHMMF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHMMF has been successfully added to your 
